# Accession Therapeutics

Source: https://onco.cc/companies/accession-therapeutics/  
OnCo record `accession-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Accession Therapeutics makes modified cold viruses that are designed to enter only cancer cells and deliver an immune-stimulating treatment inside the tumour. Its first product, ATTR-01, is in an early trial in solid tumours.

## Summary

Accession Therapeutics Limited is an Oxford, UK, company led by chief executive Bent Jakobsen, who previously gave scientific direction to the T cell receptor companies Immunocore and Adaptimmune. Its TROCEPT platform engineers a 'stealth' virus with a viral point of entry intended to target cancer cells while bypassing healthy cells, and uses it to deliver immunotherapy payloads into tumours. The lead candidate TROCEPT-01 (ATTR-01) is given intravenously; TROCEPT-02 (ATTR-02) is the second programme. In December 2025 the company announced it had raised 30.5 million pounds (40 million US dollars) from existing investors to complete the phase 1 data for ATTR-01 and take ATTR-02 into the clinic. Its first registered cancer trial, the ATTEST master protocol NCT06977737, a phase 1/2 study of intravenous ATTR-01 in selected epithelial solid tumours at sites in Spain and the UK, was posted on ClinicalTrials.gov in May 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Oxford
- Type: biotech
- Website: https://www.accessiontherapeutics.com/

## Notes

- Founding year not stated on the company website.
- The ATTR-01 payload is not named on the pages read; the registry record calls ATTR-01 a modified common cold virus that delivers an immune therapy drug into the cancer.
- The funding round name and the identity of the existing investors were not stated on the page read.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.accessiontherapeutics.com/
- Company news: 30.5 million pound financing, December 2025: https://www.accessiontherapeutics.com/news-and-events

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- trials: [A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours](https://onco.cc/trials/nct06977737/)

---
JSON: https://onco.cc/api/v1/entities/accession-therapeutics.json